In re Rivastigmine Patent Litigation

237 F.R.D. 69, 2006 U.S. Dist. LEXIS 54945, 2006 WL 2265037
CourtDistrict Court, S.D. New York
DecidedAugust 8, 2006
DocketNo. 05 MD 1661(HB)(JCF)
StatusPublished
Cited by29 cases

This text of 237 F.R.D. 69 (In re Rivastigmine Patent Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Rivastigmine Patent Litigation, 237 F.R.D. 69, 2006 U.S. Dist. LEXIS 54945, 2006 WL 2265037 (S.D.N.Y. 2006).

Opinion

MEMORANDUM AND ORDER

FRANCIS, United States Magistrate Judge.

This multidistrict litigation concerns the patent rights for rivastigmine tartrate (“ri[72]*72vastigmine”), the active ingredient in Exelon, a medication marketed by Novartis Pharmaceutical Corporation (“NPC”) for the treatment of mild to moderate dementia of the Alzheimer’s type. NPC, together with Novartis Pharma AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively, “Novartis”), has brought actions alleging that the defendants, Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratory, Inc. (collectively, “Dr. Reddy”), Watson Pharmaceuticals Inc. and Watson Laboratories, Inc. (collectively, “Watson”), and Sun Pharmaceutical Ltd. (“Sun”), have induced infringement of two patents owned by Novartis by seeking approval from the Food and Drug Administration to market generic versions of Exelon.1

The defendants seek to compel production of numerous communications that the plaintiffs have withheld primarily on the basis of attorney-client privilege.2 The communications now at issue fall into four categories.

The first category has been termed the “Swiss Motion” documents. In July 2005, the defendants submitted a motion requesting, among other things, disclosure of communications between Swiss patent agents and their clients, Swiss in-house counsel and their clients, or European patent attorneys and their clients. (Letter of Maurice N. Ross dated July 21, 2005 (“Ross 7/21/05 Ltr.” or “Swiss Motion”)). This motion was denied in relevant part on September 22, 2005, without prejudice to renew with reference to a more specifically identified group of documents. In that decision, I authorized the defendants to serve, and I ordered the plaintiffs to answer, special interrogatories providing more information about the documents for which the plaintiffs claim privilege. In December 2005, after interrogatories were served and answered but further disagreements developed between the parties, I ordered the defendants to produce all underlying Swiss Motion documents to the Court for in camera review. In January 2006, I found that the information provided by the plaintiffs to the defendants remained inadequate, and I ordered the plaintiffs to provide the defendants with additional information regarding the legal qualifications of the relevant legal professionals, as well as to provide interrogatory answers for all documents not referenced in the Swiss Motion.

The second category of documents relates to a separate motion to compel. In September 2005, the defendants requested the production of documents on the basis of alleged deficiencies in the plaintiffs’ privilege log. (Letter of Maurice N. Ross dated September 28, 2005 (“Ross 9/28/05 Ltr.,” or “Privilege Log Motion”); see Documents Subject to Defendants’ September 28, 2005 Letter, annexed as Appendix 2 to Letter of Diego Scambia dated Dec. 9, 2005 (“Scambia 12/9/05 Ltr.”)). On November 21, 2005,1 denied the defendants’ motion to require the plaintiffs to submit a revised privilege log but ordered the plaintiffs to serve the defendants and the Court with:

a letter providing sufficient information for each individual document to justify the assertion of privilege, including, for example, identification of a particular author or recipient as an attorney admitted to the bar in the United States, a U.S. patent agent, a Swiss patent attorney, a French patent agent, and so on. Where specific information is unavailable, the plaintiffs shall provide any circumstantial evidence that supports a finding of privilege.

(Nov. 21, 2005, Order). I also ordered the plaintiffs to submit all documents disputed in the Privilege Log Motion to the court for in camera review.3

[73]*73The third category of documents is a subset of the documents referenced in the Privilege Log Motion. The plaintiffs contend that a large quantity of the withheld communications pertain to foreign patent prosecutions. For those documents, rather than providing a traditional, itemized privilege log, the plaintiffs served the defendants and filed with the Court a categorical log. (Letter of Diego Scambia dated Dec. 30, 2005 (“Scambia 12/30/05 Ltr.” or “Scambia Letter of December 30, 2005”), Exh. 2). In response, the defendants argued in their Privilege Log Motion that the categorical format did not provide the information they needed to assess potential objections to the plaintiffs’ assertions of attorney-client privilege. In my November 21 Order, I sanctioned the use of a categorical log, but only under certain conditions:

In justifying the assertion of privilege [ ], the plaintiffs may treat these documents by category. However, to the extent that I find any categorical justification inadequate, all documents within the category shall he ordered produced. Further, to the extent that I find any individual document to have been improperly classified within a category, that document shall be ordered produced without further individual review.

(Nov. 21, 2005, Order) (emphasis added).

The plaintiffs have identified a fourth category of documents (the “category four documents”) that they claim were newly challenged by the defendants on February 22, 2006. (Scambia 3/24/06 Letter at 2 n. 3; Plaintiffs’ January 20 Privileged Documents Defendants Now Challenge, attached as Exh. 4 to Scambia 3/24/06 Letter). The defendants’ challenges are not new, however. Rather, they are the same objections raised in the Swiss Motion and the Privilege Log Motion. Granted, the defendants have added new documents, but they have not asserted new legal arguments. In particular, the privilege issues governing communications involving European patent attorneys and Swiss in-house attorneys-at-law have been amply briefed. To the extent the newly identified documents involve such communications, the rulings below govern. With respect to other newly identified documents, the plaintiffs are directed to reconsider their privilege claims, and the defendants their corresponding objections. Within two weeks of this Order, the parties are directed to submit to the Court a stipulation with respect to the category four documents. If the parties are unable to agree concerning any document, the parties shall include with their submission a list of the unresolved category four documents and, for each, a brief but clear statement highlighting the legal and factual bases of the disagreement.

Discussion

The attorney-client privilege functions “to encourage full and frank communication between attorneys and their clients.” United States v. Zolin, 491 U.S. 554, 562, 109 S.Ct. 2619, 105 L.Ed.2d 469 (1989). As the Supreme Court has explained, the attorney client privilege “exists to protect not only the giving of professional advice to those who can act on it but also the giving of information to the lawyer to enable him to give sound and informed advice.” Upjohn Co. v. United States, 449 U.S. 383, 390, 101 S.Ct. 677, 66 L.Ed.2d 584 (1981). Courts recognize as privileged both communications by the client to the attorney and legal advice rendered by the attorney to the client, at least to the extent that the advice reflects confidential communications between the two. In re Six Grand Jury Witnesses,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
237 F.R.D. 69, 2006 U.S. Dist. LEXIS 54945, 2006 WL 2265037, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-rivastigmine-patent-litigation-nysd-2006.